Antipyrine kinetics in patients with primary biliary cirrhosis.
Fourteen antimitochrodrial antibody-positive patients (13 women, 1 man) with biopsy-proven primary biliary cirrhosis, aged 40 to 71 years (mean, 57 years) weighing 43 to 102 kg (mean, 63 kg), along with 14 age- and sex-matched healthy controls, received a single 1.0- to 1.2-g dose of intravenous antipyrine. Plasma antipyrine levels were determined during a 12- to 24-hour period. Patients' mean serum chemistry values were: albumin, 3.9 g/dL (range, 3.1-4.4) and total bilirubin, 1.9 mg/dL (range, 0.3-10.9). Seven of the fourteen patients had cirrhosis. Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04). Within the primary biliary cirrhosis group, there was no correlation between total bilirubin and clearance (r = .09), nor did clearance vary significantly among histologic categories. Clearance of antipyrine in primary biliary cirrhosis patients is reduced by an average of 25%, but the clinical prognosticators of serum bilirubin levels and histologic grade do not correlate with or predict the degree of clearance impairment.
von Moltke
L L
LL
Tufts University School of Medicine, Boston, Massachusetts 02111.
Abernethy
D R
DR
Kaplan
M M
MM
Greenblatt
D J
DJ
D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001663:Bilirubin / Q000097:blood; D005260:Female; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology
D011433:Propranolol; D001663:Bilirubin; D000983:Antipyrine